CAPRISA 018
9 January 2022
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
Read more about the clinical trial study: Visit Healthcare Newsdesk